Literature DB >> 8788601

Gene delivery into the renal glomerulus by transfer of genetically engineered, autologous mesangial cells.

M Kitamura1, S Burton, T Yokoo, L G Fine.   

Abstract

To obviate the problem of rejection in situations where cells are used as vectors for gene delivery, the feasibility of using autologous mesangial cells cultured from renal biopsy specimens was studied for the purpose of gene transfer into the glomerulus. Using the calcium-phosphate co-precipitation method, a reporter gene which encodes bacterial beta-galactosidase was introduced into cultured mesangial cells derived from renal biopsy tissue of rats. Stable transfectants were established in the presence of a selection drug and then transferred back into the contralateral kidneys of the same animals via renal artery injection. Among 5 rats tested, expression of beta-galactosidase was detected in the isolated glomeruli from 4 injected kidneys. One week after cell injection, 31 +/- 13% of the glomeruli showed positive X-gal (5-bromo-4-chloro-3-indolyl beta- D-galactopyranoside) staining, indicating expression of the transferred gene. The use of autologous mesangial cells from biopsy specimens is thus realistic and would be useful to obviate the risk of rejection in the mesangial cell vector system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8788601

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  3 in total

1.  Creation of a reversible on/off system for site-specific in vivo control of exogenous gene activity in the renal glomerulus.

Authors:  M Kitamura
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

3.  Creation of an In vivo cytosensor using engineered mesangial cells. Automatic sensing of glomerular inflammation controls transgene activity.

Authors:  M Kitamura; H Kawachi
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.